Literature DB >> 8563835

Confidence intervals for cost/effectiveness ratios.

P Wakker1, M P Klaassen.   

Abstract

The reduction of costs is becoming increasingly important in the medical field. The relevant topic of many clinical trials is not effectiveness per se, but rather cost-effectiveness ratios. Surprisingly, no statistical tools for analyzing cost-effectiveness ratios have been provided in the medical literature yet. This paper explains the gap in the literature, and provides a first technique for obtaining confidence intervals for cost-effectiveness ratios. The technique does not use sophisticated tools to achieve maximal optimality, but seeks for tractability and ease of application while still satisfying all formal statistical requirements.

Mesh:

Year:  1995        PMID: 8563835     DOI: 10.1002/hec.4730040503

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  10 in total

1.  Handling uncertainty in economic evaluations of healthcare interventions.

Authors:  A H Briggs; A M Gray
Journal:  BMJ       Date:  1999-09-04

Review 2.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 3.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

5.  Use of confidence intervals in health economic studies.

Authors:  J A Sacristán
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

6.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

7.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

8.  Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation.

Authors:  Jonathan Karnon; Jackie Brown
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.

Authors:  N O Stålhammar; J Carlsson; R Peacock; S Müller-Lissner; M A Bigard; G B Porro; J Ponce; J Hosie; M Scott; D G Weir; C Fulton; K Gillon; K D Bardhan
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

10.  The probability of cost-effectiveness.

Authors:  Anthony O'Hagan; John W Stevens
Journal:  BMC Med Res Methodol       Date:  2002-03-11       Impact factor: 4.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.